Ampio Pharmaceuticals Inc to Discuss FDA Response Letter AP-013 Study - Investor Update Call Transcript
Good morning, and welcome to the Ampio Pharmaceuticals, Inc. Investor Update Call - FDA Response Letter AP-013 Study. (Operator Instructions)
At this time, I would like to turn the call over to Dan Stokely, Chief Financial Officer. You may begin your conference.
Thank you, operator. This is Dan Stokely, Ampio's Chief Financial Officer, and welcome to Ampio Pharmaceuticals, April 28 conference call to provide a further update with respect to the Food and Drug Administration's response to our AP-013 study. Our Chief Executive Officer, Mike Martino, will be speaking today.
Some of our comments today contain forward-looking statements, which reflect Ampio's views about some future events. Forward-looking statements made but are not always identified by words such as believe, estimate, will, may, could, can, and other similar expressions. These matters involve risks and uncertainties that could cause Ampio's actual results to materially differ from the content of those forward-looking statements.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
